Skip to main content
Top
Published in:

Open Access 05-05-2024 | Macular Degeneration | COMMENTARY

Home Optical Coherence Tomography Monitoring for Neovascular Age-Related Macular Degeneration: Transformative Technology or Cool Toy?

Authors: Ethan T. Willis, Judy E. Kim, Eric W. Schneider

Published in: Ophthalmology and Therapy | Issue 6/2024

Login to get access

Abstract

The pending introduction of home-based optical coherence tomography (OCT) in managing neovascular age-related macular degeneration (nAMD) has sparked interesting debates. Advocates assert that home-based OCT will revolutionize care of patients with nAMD, while skeptics question its real-world viability and point out its potential drawbacks. This article delves into the dichotomy, presenting the "pro" argument highlighting the transformative potential of home OCT and the "con" perspective, which scrutinizes the limitations and challenges to adapting the technology to the real-world setting. By exploring both sides of the discourse, we aim to address the promises and complexities surrounding the role of home OCT in the management of nAMD.
Literature
1.
go back to reference Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116:S1-7.CrossRefPubMed Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116:S1-7.CrossRefPubMed
2.
go back to reference Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunović H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond). 2017;31:26–44.CrossRefPubMed Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunović H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond). 2017;31:26–44.CrossRefPubMed
3.
go back to reference AREDS2-HOME Study Research Group, Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014;121:535–544. AREDS2-HOME Study Research Group, Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014;121:535–544.
4.
go back to reference Ho AC, Heier JS, Holekamp NM, et al. Real-world performance of a self-operated home monitoring system for early detection of neovascular age-related macular degeneration. J Clin Med. 2021;10:1355.CrossRefPubMedPubMedCentral Ho AC, Heier JS, Holekamp NM, et al. Real-world performance of a self-operated home monitoring system for early detection of neovascular age-related macular degeneration. J Clin Med. 2021;10:1355.CrossRefPubMedPubMedCentral
5.
go back to reference von der Burchard C, Moltmann M, Tode J, et al. Self-examination low-cost full-field OCT (SELFF-OCT) for patients with various macular diseases. Graefes Arch Clin Exp Ophthalmol. 2021;259:1503–11.CrossRefPubMed von der Burchard C, Moltmann M, Tode J, et al. Self-examination low-cost full-field OCT (SELFF-OCT) for patients with various macular diseases. Graefes Arch Clin Exp Ophthalmol. 2021;259:1503–11.CrossRefPubMed
6.
go back to reference Maloca P, Hasler PW, Barthelmes D, et al. Safety and feasibility of a novel sparse optical coherence tomography device for patient-delivered retina home monitoring. Transl Vis Sci Technol. 2018;7:8.CrossRefPubMedPubMedCentral Maloca P, Hasler PW, Barthelmes D, et al. Safety and feasibility of a novel sparse optical coherence tomography device for patient-delivered retina home monitoring. Transl Vis Sci Technol. 2018;7:8.CrossRefPubMedPubMedCentral
7.
go back to reference Chakravarthy U, Goldenberg D, Young G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731–6.CrossRefPubMed Chakravarthy U, Goldenberg D, Young G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731–6.CrossRefPubMed
8.
go back to reference Nahen K, Benyamini G, Loewenstein A. Evaluation of a self-imaging SD-OCT system for remote monitoring of patients with neovascular age-related macular degeneration. Klin Monbl Augenheilkd. 2020;237:1410–8.CrossRefPubMed Nahen K, Benyamini G, Loewenstein A. Evaluation of a self-imaging SD-OCT system for remote monitoring of patients with neovascular age-related macular degeneration. Klin Monbl Augenheilkd. 2020;237:1410–8.CrossRefPubMed
9.
go back to reference Keenan TDL, Goldstein M, Goldenberg D, et al. Prospective, longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1: 100034.CrossRefPubMedPubMedCentral Keenan TDL, Goldstein M, Goldenberg D, et al. Prospective, longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1: 100034.CrossRefPubMedPubMedCentral
10.
go back to reference Liu Y, Holekamp NM, Heier JS. Prospective, longitudinal study: daily self-imaging with home oct for neovascular age-related macular degeneration. Ophthalmol Retina. 2022;6:575–85.CrossRefPubMed Liu Y, Holekamp NM, Heier JS. Prospective, longitudinal study: daily self-imaging with home oct for neovascular age-related macular degeneration. Ophthalmol Retina. 2022;6:575–85.CrossRefPubMed
11.
go back to reference Reitan G, Kjellevold Haugen IB, Andersen K, et al. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465–74.CrossRefPubMedPubMedCentral Reitan G, Kjellevold Haugen IB, Andersen K, et al. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465–74.CrossRefPubMedPubMedCentral
12.
go back to reference Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration. Ophthalmology. 2021;128:234–47.CrossRefPubMed Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration. Ophthalmology. 2021;128:234–47.CrossRefPubMed
13.
go back to reference Heimes B, Gunnemann F, Ziegler M, et al. [Compliance of age-related macular degeneration patients undergoing anti-VEGF therapy: Analysis and suggestions for improvement]. Ophthalmologe. 2016;113:925–932. Heimes B, Gunnemann F, Ziegler M, et al. [Compliance of age-related macular degeneration patients undergoing anti-VEGF therapy: Analysis and suggestions for improvement]. Ophthalmologe. 2016;113:925–932.
14.
go back to reference Sedhom JA, Patnaik JL, McCourt EA, et al. Physician burnout in ophthalmology: U.S. survey. J Cataract Refract Surg. 2022;48:723–729. Sedhom JA, Patnaik JL, McCourt EA, et al. Physician burnout in ophthalmology: U.S. survey. J Cataract Refract Surg. 2022;48:723–729.
15.
go back to reference Rodziewicz TL, Houseman B, Hipskind JE. Medical Error Reduction and Prevention. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Rodziewicz TL, Houseman B, Hipskind JE. Medical Error Reduction and Prevention. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
16.
go back to reference Heier J. Clinical Utility of home OCT data in the management of neovascular age-related macular degeneration. Journal of Vitreoretinal Disease (in press). 2023. Heier J. Clinical Utility of home OCT data in the management of neovascular age-related macular degeneration. Journal of Vitreoretinal Disease (in press). 2023.
17.
go back to reference Chakravarthy U, Havilio M, Syntosi A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond). 2021;35:2983–90.CrossRefPubMed Chakravarthy U, Havilio M, Syntosi A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond). 2021;35:2983–90.CrossRefPubMed
18.
go back to reference Kozak I, Stewart MW. The “time in range” concept in ophthalmology. Am J Ophthalmol. 2023;256:ix–x.CrossRefPubMed Kozak I, Stewart MW. The “time in range” concept in ophthalmology. Am J Ophthalmol. 2023;256:ix–x.CrossRefPubMed
19.
go back to reference Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD Study. Ophthalmol Retina. 2017;1:314–21.CrossRefPubMed Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD Study. Ophthalmol Retina. 2017;1:314–21.CrossRefPubMed
20.
go back to reference Rufai SR, Almuhtaseb H, Paul RM, et al. A systematic review to assess the “treat-and-extend” dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye (Lond). 2017;31:1337–44.CrossRefPubMed Rufai SR, Almuhtaseb H, Paul RM, et al. A systematic review to assess the “treat-and-extend” dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye (Lond). 2017;31:1337–44.CrossRefPubMed
21.
go back to reference Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023;37:6–16.CrossRefPubMed Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023;37:6–16.CrossRefPubMed
22.
go back to reference Daien V, Finger RP, Talks JS, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2021;105:1475–9.CrossRefPubMed Daien V, Finger RP, Talks JS, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2021;105:1475–9.CrossRefPubMed
23.
24.
go back to reference Clark WL. Management of Treatment-Experienced nAMD Patients Using Home OCT Monitoring. 2023. Clark WL. Management of Treatment-Experienced nAMD Patients Using Home OCT Monitoring. 2023.
25.
go back to reference Martin DF. Update on Home OCT: DRCR Protocols. 2023. Martin DF. Update on Home OCT: DRCR Protocols. 2023.
26.
go back to reference Kim JE, Tomkins-Netzer O, Elman MJ, et al. Evaluation of a self-imaging SD-OCT system designed for remote home monitoring. BMC Ophthalmol. 2022;22:261.CrossRefPubMedPubMedCentral Kim JE, Tomkins-Netzer O, Elman MJ, et al. Evaluation of a self-imaging SD-OCT system designed for remote home monitoring. BMC Ophthalmol. 2022;22:261.CrossRefPubMedPubMedCentral
27.
go back to reference Kiss S, Campbell J, Almony A, et al. Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology. 2020;127:1179–88.CrossRefPubMed Kiss S, Campbell J, Almony A, et al. Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology. 2020;127:1179–88.CrossRefPubMed
28.
go back to reference Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49,485 eyes. Ophthalmol Retina. 2020;4:19–30.CrossRefPubMed Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49,485 eyes. Ophthalmol Retina. 2020;4:19–30.CrossRefPubMed
29.
go back to reference Yu HJ, Kiernan DF, Eichenbaum D, et al. Home monitoring of age-related macular degeneration: utility of the Foresee home device for detection of neovascularization. Ophthalmol Retina. 2021;5:348–56.CrossRefPubMed Yu HJ, Kiernan DF, Eichenbaum D, et al. Home monitoring of age-related macular degeneration: utility of the Foresee home device for detection of neovascularization. Ophthalmol Retina. 2021;5:348–56.CrossRefPubMed
30.
31.
go back to reference CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
32.
go back to reference Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–1056. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–1056.
Metadata
Title
Home Optical Coherence Tomography Monitoring for Neovascular Age-Related Macular Degeneration: Transformative Technology or Cool Toy?
Authors
Ethan T. Willis
Judy E. Kim
Eric W. Schneider
Publication date
05-05-2024
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 6/2024
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-024-00953-8

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more